PHIO Stock Price, Phio Pharmaceuticals Quote, Chart

Market Summary

USD0.81+0.08

Market Closed

10.96%

PHIO Stock Price

View Fullscreen

PHIO RSI Chart

PHIO Valuation

Market Cap

3.4M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

172.74

EV/EBITDA

0.25

Price/Free Cashflow

-0.33

PHIO Price/Sales (Trailing)

PHIO Profitability

EBT Margin

-54666.67%

Return on Equity

-167.34%

Return on Assets

-136.85%

Free Cashflow Yield

-300.04%

PHIO Fundamentals

PHIO Revenue

Revenue (TTM)

21.0K

PHIO Earnings

Earnings (TTM)

-9.4M

Earnings Growth (Yr)

40.2%

Earnings Growth (Qtr)

-13.67%

Breaking Down PHIO Revenue

52 Week Range

0.755.29

(Low)(High)

Last 7 days

-5.2%

Last 30 days

12.3%

Last 90 days

10.6%

Trailing 12 Months

-80.6%

How does PHIO drawdown profile look like?

PHIO Financial Health

Current Ratio

5.48

PHIO Investor Care

Shares Dilution (1Y)

205.18%

Diluted EPS (TTM)

-2.89

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2019	136.0K	78.0K	21.0K	21.0K
2018	45.8K	76.5K	107.3K	138.0K
2017	0	0	0	15.0K
2016	10.0K	19.0K	19.0K	19.0K
2015	76.0K	64.0K	48.0K	34.0K
2014	375.0K	162.0K	86.0K	71.0K
2013	172.5K	248.0K	323.5K	399.0K
2012	0	0	0	97.0K
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Phio Pharmaceuticals Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	kontulis caitlin	sold (taxes)	-320	0.958	-335	secretary & vp finance & admin
Feb 26, 2024	bitterman robert j	bought	2,275	0.91	2,500	president & ceo
Feb 20, 2024	bitterman robert j	sold (taxes)	-1,371	0.76	-1,804	president & ceo
Feb 17, 2024	kontulis caitlin	sold (taxes)	-345	0.66	-523	secretary & vp finance & admin
Feb 15, 2024	kontulis caitlin	sold (taxes)	-427	0.65	-658	secretary & vp finance & admin
Oct 01, 2023	bitterman robert j	sold (taxes)	-1,384	1.51	-917	president & ceo
Jul 01, 2023	bitterman robert j	bought	2,840	2.84	1,000	president & ceo
Jun 30, 2023	bitterman robert j	bought	2,880	2.88	1,000	president & ceo
Jun 14, 2023	ferrara robert l	bought	6,200	3.1	2,000	-
Mar 01, 2023	kontulis caitlin	sold (taxes)	-1,839	5.49	-335	secretary & vp finance & admin

Which funds bought or sold PHIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	MORGAN STANLEY	sold off	-100	-95.00	-	-%
May 15, 2024	Cetera Investment Advisers	sold off	-100	-12,856	-	-%
May 15, 2024	SABBY MANAGEMENT, LLC	sold off	-100	-131,247,000	-	-%
May 15, 2024	Cetera Advisors LLC	new	-	20,683	20,683	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-0.28	-468	3,874	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-1,879	15,970	-%
May 15, 2024	CITADEL ADVISORS LLC	sold off	-100	-24,201	-	-%
May 14, 2024	Anson Funds Management LP	sold off	-100	-119,643	-	-%
May 13, 2024	RENAISSANCE TECHNOLOGIES LLC	sold off	-100	-16,000	-	-%
May 13, 2024	BANK OF MONTREAL /CAN/	unchanged	-	-1,898	17,102	-%

Are Funds Buying or Selling PHIO?

Are funds buying PHIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PHIO

No. of Funds

Unveiling Phio Pharmaceuticals Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	9.99%	891,401	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	5.6%	811,832	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	5.7%	811,832	SC 13G/A
Jan 20, 2022	empery asset management, lp	4.99%	789,063	SC 13G/A
Feb 19, 2021	empery asset management, lp	6.76%	899,684	SC 13G
Feb 16, 2021	cvi investments, inc.	4.0%	228,896	SC 13G/A
Jan 29, 2021	intracoastal capital, llc	7.2%	445,383	SC 13G/A
Jan 05, 2021	sabby management, llc	4.99%	288,452	SC 13G/A
Apr 09, 2020	cvi investments, inc.	9.3%	428,266	SC 13G
Apr 08, 2020	armistice capital, llc	4.99%	240,592	SC 13G

Recent SEC filings of Phio Pharmaceuticals Corp

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 08, 2024	DEFA14A	DEFA14A
May 08, 2024	DEF 14A	DEF 14A
May 08, 2024	ARS	ARS
Apr 22, 2024	PRE 14A	PRE 14A
Apr 02, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Mar 05, 2024	4	Insider Trading
Feb 27, 2024	4	Insider Trading

Peers (Alternatives to Phio Pharmaceuticals Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	27.86%	5.69%	-8.52	7.43	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.1B	2.0B	3.08%	-21.73%	-57.61	9.55	75.20%	68.82%
BMRN	14.6B	2.5B	-15.33%	-16.61%	71.11	5.91	13.74%	186.89%
INCY	12.8B	3.8B	6.86%	-11.90%	17.13	3.39	8.58%	129.81%
MID-CAP
BBIO	5.8B	107.9M	23.06%	120.60%	-10.63	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.99%	-52.96%	-12.22	9.73	394.93%	39.61%
AXSM	3.7B	251.0M	12.53%	-1.35%	-12.4	14.64	73.58%	-86.73%
ARWR	3.1B	240.7M	5.66%	-32.59%	-6.6	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-13.11%	-34.57%	-1.4K	3.01	56.43%	98.83%
SMALL-CAP
NVAX	2.0B	996.6M	260.65%	85.68%	-5.07	2.03	-26.66%	65.49%
CPRX	1.9B	411.3M	5.34%	30.65%	29.69	4.7	60.38%	-34.49%
CRBP	489.5M	881.7K	11.38%	343.80%	-14.5	481.06	-77.61%	33.36%
INO	330.9M	4.9M	32.47%	47.80%	-2.65	67.99	-54.97%	48.23%
IBIO	15.7M	2.1M	-6.67%	89.09%	-0.68	7.61	-13.45%	69.54%

Phio Pharmaceuticals Corp News

Latest updates

Phio Pharmaceuticals Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2016Q4	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q3	2014Q2	2014Q1
Revenue	-	-	-	-	21.00	-	57.00	58.00	23.00	12.00	-	-	9.00	10.00	-	-	-	34.00	14.00	16.00	12.00	29.00
Operating Expenses	26.3%	2,669	2,113	2,059	2,167	1,734	1,549	1,957	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	53.7%	1,646	1,071	913	1,078	790	711	774	901	-	-	-	-	-	-	-	-	-	-	-	-	-
R&D Expenses	-1.8%	1,023	1,042	1,146	1,089	944	838	1,183	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-1,727	-1,493	-1,901	-2,239	-2,002	-2,339	-2,212	-2,212	-	-	-	-	-	-	-	-	-
Net Income	-27.0%	-2,660	-2,094	-2,035	-2,119	-1,727	-1,493	-1,901	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-26.8%	6,853	9,364	9,539	12,296	9,707	12,814	15,791	20,144	22,162	25,170	27,943	31,657	33,856	15,739	18,239	20,211	14,305	8,039	10,079	12,108	13,678
Current Assets	-26.5%	6,848	9,322	9,328	12,035	9,404	12,446	15,377	19,688	21,667	24,727	27,450	31,155	33,322	15,164	17,620	19,554	13,601	7,300	9,292	11,373	12,913
Cash Equivalents	-23.7%	6,475	8,490	8,457	11,357	9,085	11,831	14,534	18,070	20,509	24,107	26,579	29,475	32,745	14,294	16,918	18,914	13,334	6,984	8,759	10,866	12,796
Net PPE	-66.7%	2.00	6.00	142	157	167	183	198	206	215	133	153	142	145	157	173	183	202	210	231	152	155
Liabilities	-100.0%	-	1,634	2,326	2,392	2,396	1,974	2,264	3,141	2,711	3,238	2,697	2,812	2,456	2,722	2,786	2,478	2,320	2,291	2,474	2,401	2,016
Current Liabilities	-23.6%	1,249	1,634	2,326	2,392	2,396	1,939	2,194	3,037	2,573	3,068	2,495	2,578	2,191	2,196	2,230	1,893	1,937	1,880	2,036	1,936	1,516
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	231	231	231	-	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	231	231	231	-	-	-	-	-
Shareholder's Equity	-27.5%	5,604	7,730	7,213	9,904	7,311	10,838	13,527	17,003	19,451	21,932	25,246	28,845	31,400	13,017	15,453	17,733	11,985	5,748	7,605	9,707	11,662
Retained Earnings	-1.5%	-141,360	-139,206	-137,311	-134,531	-131,982	-128,380	-125,649	-122,073	-119,542	-116,900	-113,449	-109,707	-107,020	-103,613	-101,151	-98,842	-97,170	-94,819	-92,159	-90,065	-88,030
Additional Paid-In Capital	0.0%	146,964	146,936	144,524	144,435	139,293	139,218	139,175	139,075	138,992	138,832	138,694	138,551	138,419	116,629	116,603	116,574	109,154	100,566	99,761	99,769	99,690
Accumulated Depreciation	-100.0%	-	1,136	-	-	-	1,175	-	-	-	-	-	-	-	1,122	-	-	-	1,048	-	-	-
Shares Outstanding	22.5%	4,592	3,747	2,307	1,985	1,151	1,139	1,136	1,138	1,130	1,128	1,049	1,010	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	5,700	-	-	-	9,500	-	-	-	30,488	-	-	-	12,583	-	-	-	9,357	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	15.1%	-2,011	-2,370	-2,900	-2,771	-2,708	-2,705	-3,526	-2,429	-3,469	-2,471	-2,866	-3,255	-3,266	-2,623	-1,971	-2,032	-2,176	-2,546	-1,991	-1,933	-2,175
Share Based Compensation	255.6%	32.00	9.00	89.00	94.00	111	42.00	103	83.00	186	138	143	132	67.00	26.00	37.00	30.00	43.00	31.00	47.00	62.00	160
Cashflow From Investing	-	-	-	-	-5.00	-	-	-7.00	-10.00	-104	-	-30.00	-15.00	-6.00	-1.00	-8.00	-	-10.00	5.00	-61.00	-15.00	-1.00
Cashflow From Financing	-100.2%	-4.00	2,403	-	5,048	-38.00	2.00	-3.00	-	-25.00	-1.00	-	-	21,723	-	-17.00	7,612	8,536	766	-55.00	18.00	43.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PHIO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 1,148	$ 2,134
General and administrative	1,061	1,468
Total operating expenses	2,209	3,602
Operating loss	(2,209)	(3,602)
Total other income, net	55	0
Net loss	$ (2,154)	$ (3,602)
Net loss per common share:
Net loss per common share, Basic	$ (0.47)	$ (3.15)
Net loss per common share, Diluted	$ (0.47)	$ (3.15)
Weighted average number of common shares outstanding:
Weighted average number of common shares outstanding, Basic	4,580,072	1,142,213
Weighted average number of common shares outstanding, Diluted	4,580,072	1,142,213

PHIO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 6,475	$ 8,490
Prepaid expenses and other current assets	373	832
Total current assets	6,848	9,322
Right of use asset	0	33
Property and equipment, net	2	6
Other assets	3	3
Total assets	6,853	9,364
Current liabilities:
Accounts payable	320	657
Accrued expenses	929	942
Lease liability	0	35
Total current liabilities	1,249	1,634
Commitments and contingencies (Note 2)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 100,000,000 shares authorized; no shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Common stock, $0.0001 par value, 100,000,000 shares authorized; 4,591,700 and 3,747,329 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	146,964	146,936
Accumulated deficit	(141,360)	(139,206)
Total stockholders’ equity	5,604	7,730
Total liabilities and stockholders’ equity	$ 6,853	$ 9,364

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Robert J. Bitterman
WEBSITE	phiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Phio Pharmaceuticals Corp Frequently Asked Questions

What is the ticker symbol for Phio Pharmaceuticals Corp? What does PHIO stand for in stocks?

PHIO is the stock ticker symbol of Phio Pharmaceuticals Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Phio Pharmaceuticals Corp (PHIO)?

As of Thu May 16 2024, market cap of Phio Pharmaceuticals Corp is 3.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PHIO stock?

You can check PHIO's fair value in chart for subscribers.

What is the fair value of PHIO stock?

You can check PHIO's fair value in chart for subscribers. The fair value of Phio Pharmaceuticals Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Phio Pharmaceuticals Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PHIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Phio Pharmaceuticals Corp a good stock to buy?

The fair value guage provides a quick view whether PHIO is over valued or under valued. Whether Phio Pharmaceuticals Corp is cheap or expensive depends on the assumptions which impact Phio Pharmaceuticals Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PHIO.

What is Phio Pharmaceuticals Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, PHIO's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 172.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PHIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Phio Pharmaceuticals Corp's stock?

In the past 10 years, Phio Pharmaceuticals Corp has provided -0.713 (multiply by 100 for percentage) rate of return.